Results 51 to 60 of about 22,239 (295)

Dipeptidyl Peptidase IV Inhibitors and Ischemic Myocardial Injury

Journal of Cardiovascular Pharmacology and Therapeutics, 2014
Diabetes mellitus is a major risk factor for cardiovascular events and patient death. Many animal and clinical studies are now being conducted exploring the potential of antidiabetic drugs such as glucagon-like peptide 1 (GLP-1) agonists and dipeptidyl peptidase IV (DPP-IV) inhibitors to improve cardiovascular outcomes.
Alyssa H, Yoon, Yumei, Ye, Yochai, Birnbaum   +2 more
openaire   +2 more sources

Autoimmune Encephalitis in Acute Care—Pathology, Diagnosis, and Management

Advanced Science, EarlyView.
ABSTRACT Autoimmune encephalitis (AE) is characterized by immune‐mediated inflammation of the brain parenchyma, presenting with various neurological syndromes, including but not limited to seizures, altered consciousness, neuropsychiatric symptoms, and movement disorders.
Suneesh Thilak, David Okoh, William Scotton, Shanika Samarasekera, Vikram Patil, Suresh Renukappa, Andrew Macduff, Subashini Suresh, Rajeev Krishnadas, Tonny Veenith   +9 more
wiley   +1 more source

Identification of phytoconstituents from Houttuynia cordata Thunb. as dipeptidyl peptidase-IV and sodium glucose cotransporter 2 inhibitors guided by molecular docking

Phytomedicine Plus
Purpose: Houttuynia cordata Thunb. is an edible medicinal herb belonging to the Saururaceae family. Although the effects of the plant extracts on several diabetic-related parameters have been documented in the past, there is no documentation of the ...
Careen Liza Pakyntein, Daiahun Thabah, Anita Kumari Rai, Donkupar Syiem   +3 more
doaj   +1 more source

Two-Year Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Empagliflozin in Drug-Naïve Type 2 Diabetes Mellitus Patients [PDF]

Diabetes & Metabolism Journal
Background We investigated the long-term efficacy and safety of initial triple therapy using metformin, a dipeptidyl peptidase-4 inhibitor, and a sodium-glucose cotransporter-2 inhibitor, in patients with type 2 diabetes mellitus. Methods We enrolled 170
Young-Hwan Park, Minji Sohn, So Yeon Lee, Soo Lim   +3 more
doaj   +1 more source

Fast Skeletal Muscle Troponin and Tropomyosin as a Dietary Source of Antidiabetic and Antihypertensive Bioactive Peptides: An In Silico Study

Vitae, 2023
Background : The nutraceutical properties of food hydrolysates rely on multiple biochemical interactions involving the modulation of enzymes and cellular receptors.
Jorge Andrés Barrero, María Alejandra Barrero, Angélica María González Clavijo, Claudia Marcela Cruz   +3 more
doaj   +1 more source

Identifying Cytokine Motif‐Containing, Immunomodulatory Bacterial Proteins in Human Gut Microbiome

Advanced Science, EarlyView.
By building and constructing HMM (Upper left, blue), the authors identify CMCPs in bacteria genomes and CRC related metagenomes and enriched CRC‐related CMCPs (Upper right, blue). They analyze sequence and structural similarity of hits (Lower left, green), test function with engineered EcN delivered to tumors in a mouse tumor model (Lower right, pink ...
Ziyu Wang, Siqi Guo, Jing Li, Qianqian Huang, Jing Ning, Binbin Xia, Xun Lv, Xiang Liu, Zeyu Gao, Jine Li, Longchao Liu, Moshi Song, Jun Wang   +12 more
wiley   +1 more source

The multiple actions of dipeptidyl peptidase 4 (DPP-4) and its pharmacological inhibition on bone metabolism: a review

Diabetology & Metabolic Syndrome
Background Dipeptidyl peptidase 4 (DPP-4) plays a crucial role in breaking down various substrates. It also has effects on the insulin signaling pathway, contributing to insulin resistance, and involvement in inflammatory processes like obesity and type ...
L. M. Pechmann, F. I. Pinheiro, V. F. C. Andrade, C. A. Moreira   +3 more
doaj   +1 more source

Acute Kidney Injury Associated with Linagliptin

Case Reports in Endocrinology, 2016
Linagliptin is a dipeptidyl peptidase-IV (DPP-IV) inhibitor that is approved for the treatment of type 2 diabetes mellitus. About 5% of linagliptin is eliminated by the kidneys and no dose adjustment is recommended in kidney impairment. We report a first
Deepak K. Nandikanti, Elvira O. Gosmanova, Aidar R. Gosmanov   +2 more
doaj   +1 more source

Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus. [PDF]

, 2014
peer reviewedPatients with type 2 diabetes mellitus have an increased risk of chronic liver disease (CLD) such as non-alcoholic fatty liver disease and steatohepatitis, and about one-third of cirrhotic patients have diabetes.
Scheen, André
core   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source